Jennifer A Janusz1, Bonita P Klein-Tasman2, Jonathan M Payne2, Pamela L Wolters2, Heather L Thompson2, Staci Martin2, Peter de Blank2, Nicole Ullrich2, Allison Del Castillo2, Maureen Hussey2, Kristina K Hardy2, Kristina Haebich2, Tena Rosser2, Mary Anne Toledo-Tamula2, Karin S Walsh2. 1. From the Children's Hospital Colorado and University of Colorado School of Medicine (J.A.J.), Aurora; Department of Psychology (B.P.K.-T.), University of Wisconsin-Milwaukee; Murdoch Children's Research Institute and Department of Pediatrics (J.M.P., K.H.), University of Melbourne, Australia; Pediatric Oncology Branch (P.L.W., S.M., M.A.T.-T.), National Cancer Institute, Bethesda, MD; Department of Communication Sciences and Disorders (H.L.T.), California State University, Sacramento; University of Cincinnati Medical Center (P.d.B.), OH; Boston Children's Hospital (N.U.), MA; Children's National Hospital, Gilbert NF Institute (A.d.C., K.K.H., K.S.W.), Washington, DC; Children's Tumor Foundation (M.H.), New York, NY; The George Washington School of Medicine (K.K.H., K.S.W.), Washington, DC; Children's Hospital Los Angeles (T.R.), CA; and Leidos Biomedical Research, Inc. (M.A.T.-T.), Frederick, MD. jennifer.janusz@childrenscolorado.org. 2. From the Children's Hospital Colorado and University of Colorado School of Medicine (J.A.J.), Aurora; Department of Psychology (B.P.K.-T.), University of Wisconsin-Milwaukee; Murdoch Children's Research Institute and Department of Pediatrics (J.M.P., K.H.), University of Melbourne, Australia; Pediatric Oncology Branch (P.L.W., S.M., M.A.T.-T.), National Cancer Institute, Bethesda, MD; Department of Communication Sciences and Disorders (H.L.T.), California State University, Sacramento; University of Cincinnati Medical Center (P.d.B.), OH; Boston Children's Hospital (N.U.), MA; Children's National Hospital, Gilbert NF Institute (A.d.C., K.K.H., K.S.W.), Washington, DC; Children's Tumor Foundation (M.H.), New York, NY; The George Washington School of Medicine (K.K.H., K.S.W.), Washington, DC; Children's Hospital Los Angeles (T.R.), CA; and Leidos Biomedical Research, Inc. (M.A.T.-T.), Frederick, MD.
Abstract
OBJECTIVE: To review parent-report social skills measures to identify and recommend consensus outcomes for use in clinical trials of social deficit in children and adolescents (ages 6-18 years) with neurofibromatosis type 1 (NF1). METHODS: Searches were conducted via PubMed and ClinicalTrials.gov to identity social skills outcome measures with English language versions used in clinical trials in the past 5 years with populations with known social skills deficits, including attention-deficit/hyperactivity disorder and autism spectrum disorder (ASD). Measures were rated by the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) Neurocognitive Committee on patient characteristics, use in published studies, domains assessed, availability of standard scores, psychometric properties, and feasibility to determine their appropriateness for use in NF1 clinical trials. RESULTS: Two measures were ultimately recommended by the committee: the Social Responsiveness Scale-2 (SRS-2) and the Social Skills Improvement System-Rating Scale (SSIS-RS). CONCLUSIONS: Each of the 2 measures assesses different aspects of social functioning. The SSIS-RS is appropriate for studies focused on broader social functioning; the SRS-2 is best for studies targeting problematic social behaviors associated with ASD. Researchers will need to consider the goals of their study when choosing a measure, and specific recommendations for their use are provided.
OBJECTIVE: To review parent-report social skills measures to identify and recommend consensus outcomes for use in clinical trials of social deficit in children and adolescents (ages 6-18 years) with neurofibromatosis type 1 (NF1). METHODS: Searches were conducted via PubMed and ClinicalTrials.gov to identity social skills outcome measures with English language versions used in clinical trials in the past 5 years with populations with known social skills deficits, including attention-deficit/hyperactivity disorder and autism spectrum disorder (ASD). Measures were rated by the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) Neurocognitive Committee on patient characteristics, use in published studies, domains assessed, availability of standard scores, psychometric properties, and feasibility to determine their appropriateness for use in NF1 clinical trials. RESULTS: Two measures were ultimately recommended by the committee: the Social Responsiveness Scale-2 (SRS-2) and the Social Skills Improvement System-Rating Scale (SSIS-RS). CONCLUSIONS: Each of the 2 measures assesses different aspects of social functioning. The SSIS-RS is appropriate for studies focused on broader social functioning; the SRS-2 is best for studies targeting problematic social behaviors associated with ASD. Researchers will need to consider the goals of their study when choosing a measure, and specific recommendations for their use are provided.
Authors: James G Waxmonsky; Daniel A Waschbusch; William E Pelham; Lillian Draganac-Cardona; Bryan Rotella; Lynn Ryan Journal: J Clin Psychiatry Date: 2010-06-29 Impact factor: 4.384
Authors: Christine M Freitag; Katrin Jensen; Leyla Elsuni; Michael Sachse; Beate Herpertz-Dahlmann; Martin Schulte-Rüther; Susann Hänig; Alexander von Gontard; Luise Poustka; Tanja Schad-Hansjosten; Christina Wenzl; Judith Sinzig; Regina Taurines; Julia Geißler; Meinhard Kieser; Hannah Cholemkery Journal: J Child Psychol Psychiatry Date: 2015-12-30 Impact factor: 8.982
Authors: Shruti Garg; Annukka Lehtonen; Susan M Huson; Richard Emsley; Dorothy Trump; D Gareth Evans; Jonathan Green Journal: Dev Med Child Neurol Date: 2012-11-16 Impact factor: 5.449
Authors: Andrew J O Whitehouse; Kandice J Varcin; Gail A Alvares; Josephine Barbaro; Catherine Bent; Maryam Boutrus; Lacey Chetcuti; Matthew N Cooper; Alena Clark; Emma Davidson; Stefanie Dimov; Cheryl Dissanayake; Jane Doyle; Megan Grant; Teresa Iacono; Murray Maybery; Sarah Pillar; Michelle Renton; Catherine Rowbottam; Nancy Sadka; Leonie Segal; Vicky Slonims; Carol Taylor; Scott Wakeling; Ming Wai Wan; John Wray; Jonathan Green; Kristelle Hudry Journal: Lancet Child Adolesc Health Date: 2019-07-16
Authors: Ellen Plasschaert; Mie-Jef Descheemaeker; Lien Van Eylen; Ilse Noens; Jean Steyaert; Eric Legius Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2014-11-12 Impact factor: 3.568
Authors: Shruti Garg; Ellen Plasschaert; Mie-Jef Descheemaeker; Susan Huson; Martine Borghgraef; Annick Vogels; D Gareth Evans; Eric Legius; Jonathan Green Journal: J Autism Dev Disord Date: 2015-06
Authors: Linda J Pfiffner; Mary E Rooney; Yuanyuan Jiang; Lauren M Haack; Allyson Beaulieu; Keith McBurnett Journal: J Am Acad Child Adolesc Psychiatry Date: 2018-02-08 Impact factor: 8.829
Authors: Stephan Cj Huijbregts; Marisa Loitfelder; Serge A Rombouts; Hanna Swaab; Berit M Verbist; Enrico B Arkink; Mark A Van Buchem; Ilya M Veer Journal: J Neurodev Disord Date: 2015-10-15 Impact factor: 4.025